These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31664224)

  • 1. JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis.
    Nocturne G; Pascaud J; Ly B; Tahmasebi F; Mariette X
    Cell Mol Immunol; 2020 May; 17(5):552-553. PubMed ID: 31664224
    [No Abstract]   [Full Text] [Related]  

  • 2. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease.
    Hernandez-Rocha C; Vande Casteele N
    Curr Opin Pharmacol; 2020 Dec; 55():99-109. PubMed ID: 33207299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models.
    Bottos A; Gotthardt D; Gill JW; Gattelli A; Frei A; Tzankov A; Sexl V; Wodnar-Filipowicz A; Hynes NE
    Nat Commun; 2016 Jul; 7():12258. PubMed ID: 27406745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of JAK inhibitors in the treatment of progressive systemic sclerosis.
    Deverapalli SC; Rosmarin D
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):e328. PubMed ID: 29444362
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus.
    Dulak-Lis M; Bujak A; Gala K; Banach M; Kędzierska U; Miszkiel J; Hucz-Kalitowska J; Mroczkiewicz M; Stypik B; Szymczak K; Gunerka P; Dubiel K; Zygmunt BM; Wieczorek M; Pieczykolan JS
    J Pharmacol Sci; 2021 Apr; 145(4):340-348. PubMed ID: 33712286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
    Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
    J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis.
    Vian L; Le MT; Gazaniga N; Kieltyka J; Liu C; Pietropaolo G; Dell'Orso S; Brooks SR; Furumoto Y; Thomas CJ; O'Shea JJ; Sciumè G; Gadina M
    Front Immunol; 2019; 10():2972. PubMed ID: 31921209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK Inhibitors: Back to Small Molecules for the Treatment of IBD.
    Panés J; Vermeire S
    J Crohns Colitis; 2020 Aug; 14(Supplement_2):S711-S712. PubMed ID: 32737980
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
    Wei X; Wu J; Zhao G; Galdamez J; Lele SM; Wang X; Liu Y; Soni DM; Purdue PE; Mikuls TR; Goldring SR; Wang D
    Mol Pharm; 2018 Aug; 15(8):3456-3467. PubMed ID: 29966420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of severe lichen planus with the JAK inhibitor tofacitinib.
    Damsky W; Wang A; Olamiju B; Peterson D; Galan A; King B
    J Allergy Clin Immunol; 2020 Jun; 145(6):1708-1710.e2. PubMed ID: 32018031
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
    Koga T; Sato T; Umeda M; Fukui S; Horai Y; Kawashiri SY; Iwamoto N; Ichinose K; Nakamura H; Kawakami A
    Clin Immunol; 2016 Dec; 173():147-148. PubMed ID: 27720846
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
    Aung WW; Wang C; Xibei J; Horii M; Mizumaki K; Kano M; Okamura A; Kobayashi T; Matsushita T
    J Dermatol Sci; 2021 Mar; 101(3):174-184. PubMed ID: 33451905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    Lefevre PLC; Vande Casteele N
    J Crohns Colitis; 2020 Aug; 14(Supplement_2):S725-S736. PubMed ID: 32160283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
    Qiu Q; Feng Q; Tan X; Guo M
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):547-554. PubMed ID: 31059310
    [No Abstract]   [Full Text] [Related]  

  • 15. Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis.
    Cao XY; Zhao JL; Hou Y; Wang FD; Lu ZH
    Clin Exp Rheumatol; 2020; 38(3):567-568. PubMed ID: 31820721
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversal of Alopecia Universalis by Tofacitinib: A Case Report.
    Scheinberg M; Ferreira SB
    Ann Intern Med; 2016 Nov; 165(10):750-751. PubMed ID: 27842401
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of recalcitrant nodular prurigo with tofacitinib.
    Molloy OE; Kearney N; Byrne N; Kirby B
    Clin Exp Dermatol; 2020 Oct; 45(7):918-920. PubMed ID: 32484964
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
    Hassold N; Seystahl K; Kempf K; Urlaub D; Zekl M; Einsele H; Watzl C; Wischhusen J; Seggewiss-Bernhardt R
    Int J Cancer; 2012 Sep; 131(6):E916-27. PubMed ID: 22419518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic Tofacitinib-A More Affordable JAK Inhibitor.
    Goll GL; Kvien TK
    Mayo Clin Proc; 2024 Jan; 99(1):4-6. PubMed ID: 38176834
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.